IgA nephropathy: a review of existing and emerging therapies

IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide. Recently, there have been multiple advances in the understanding of IgAN pathophysiology and therapeutic options. Despite the advent of new treatment options, individual risk stratification of the disease course...

Descripción completa

Detalles Bibliográficos
Autores principales: Noor, Sahibzadi Mahrukh, Abuazzam, Farah, Mathew, Roy, Zhang, Zhiwei, Abdipour, Amir, Norouzi, Sayna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Nephrology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10479631/
https://www.ncbi.nlm.nih.gov/pubmed/37675358
http://dx.doi.org/10.3389/fneph.2023.1175088
_version_ 1785101633907064832
author Noor, Sahibzadi Mahrukh
Abuazzam, Farah
Mathew, Roy
Zhang, Zhiwei
Abdipour, Amir
Norouzi, Sayna
author_facet Noor, Sahibzadi Mahrukh
Abuazzam, Farah
Mathew, Roy
Zhang, Zhiwei
Abdipour, Amir
Norouzi, Sayna
author_sort Noor, Sahibzadi Mahrukh
collection PubMed
description IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide. Recently, there have been multiple advances in the understanding of IgAN pathophysiology and therapeutic options. Despite the advent of new treatment options, individual risk stratification of the disease course and choosing the best treatment strategy for the patient remains challenging. A multitude of clinical trials is ongoing, opening multiple opportunities for enrollment. In this brief review we discuss the current approach to the management of IgAN and highlight the ongoing clinical trials.
format Online
Article
Text
id pubmed-10479631
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104796312023-09-06 IgA nephropathy: a review of existing and emerging therapies Noor, Sahibzadi Mahrukh Abuazzam, Farah Mathew, Roy Zhang, Zhiwei Abdipour, Amir Norouzi, Sayna Front Nephrol Nephrology IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide. Recently, there have been multiple advances in the understanding of IgAN pathophysiology and therapeutic options. Despite the advent of new treatment options, individual risk stratification of the disease course and choosing the best treatment strategy for the patient remains challenging. A multitude of clinical trials is ongoing, opening multiple opportunities for enrollment. In this brief review we discuss the current approach to the management of IgAN and highlight the ongoing clinical trials. Frontiers Media S.A. 2023-05-23 /pmc/articles/PMC10479631/ /pubmed/37675358 http://dx.doi.org/10.3389/fneph.2023.1175088 Text en Copyright © 2023 Noor, Abuazzam, Mathew, Zhang, Abdipour and Norouzi https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Nephrology
Noor, Sahibzadi Mahrukh
Abuazzam, Farah
Mathew, Roy
Zhang, Zhiwei
Abdipour, Amir
Norouzi, Sayna
IgA nephropathy: a review of existing and emerging therapies
title IgA nephropathy: a review of existing and emerging therapies
title_full IgA nephropathy: a review of existing and emerging therapies
title_fullStr IgA nephropathy: a review of existing and emerging therapies
title_full_unstemmed IgA nephropathy: a review of existing and emerging therapies
title_short IgA nephropathy: a review of existing and emerging therapies
title_sort iga nephropathy: a review of existing and emerging therapies
topic Nephrology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10479631/
https://www.ncbi.nlm.nih.gov/pubmed/37675358
http://dx.doi.org/10.3389/fneph.2023.1175088
work_keys_str_mv AT noorsahibzadimahrukh iganephropathyareviewofexistingandemergingtherapies
AT abuazzamfarah iganephropathyareviewofexistingandemergingtherapies
AT mathewroy iganephropathyareviewofexistingandemergingtherapies
AT zhangzhiwei iganephropathyareviewofexistingandemergingtherapies
AT abdipouramir iganephropathyareviewofexistingandemergingtherapies
AT norouzisayna iganephropathyareviewofexistingandemergingtherapies

Ejemplares similares